APPROVAL OF FOSRENOL IN GERMANY TRIGGERS U.S.$3 MILLION PAYMENT TO ANORMED

AnorMED Inc. announced that under the terms of an existing agreement, AnorMED will receive a U.S.$3 million milestone payment from Shire Pharmaceuticals Group, plc based on the recent licensing approval received in Germany by Shire to sell FOSRENOL as a treatment for high phosphate levels in the blood, which occurs in patients undergoing dialysis as a result of chronic kidney failure. Yahoo Finance (http://biz.yahoo.com/prnews/060918/to304.html?.v=5)